Drug Search Results
More Filters [+]

Sodium chloride

Alternative Names: sodium chloride, sodium-chloride, sodium chloride 0.9% in plastic container, sodio cloruro, natriumklorid, natriumchlorid, natrijev klorid, natrii chloridi infundibile, cloruro de sodio, cloreto de sodio, broncho saline, diluent, nacellate solution 0.9% - 500ml, nacellate solution 0.9% - 100ml, nacellate solution 0.9% - 250ml, hespan, nacellate solution 0.9% - 1000ml, corvatrol 0.9%, moviprep, plenvu, golytely, nulytely, balanced salt, tis-u-sol, procalamine, colyte with flavor packs, aminosyn ii 8.5% w/ electrolytes, colyte-flavored, glycoprep, go-evac, aminosyn 3.5% m in plastic container, isolyte s ph 7.4 in plastic container, lactated ringer's in plastic container, plasma-lyte 56 in plastic container, isolyte e in plastic container, prismasol bgk 4/0 in plastic container, ringer's in plastic container, prismasol b22gk 2/0 in plastic container, aminosyn 8.5% w/electrolytes, aminosyn ii 3.5% m in plastic container, isolyte s in plastic container, phoxillum b22k 4/0 in plastic container, prismasol bk 0/3.5 in plastic container, prismasol bgk 4/2.5 in plastic container, travasol 5.5% sulfite free w/ electrolytes in plastic container, plasma-lyte r in plastic container, prismasol bgk 4/3.5 in plastic container, travasol 3.5% sulfite free w/ electrolytes in plastic container, colyte, bss, physiolyte in plastic container, normosol-r in plastic container, e-z-em prep lyte, prismasol b22gk 4/2.5 in plastic container, tis-u-sol in plastic container, aminosyn 7% w/ electrolytes, aminosyn ii 7% w/ electrolytes, physiosol ph 7.4 in plastic container, plegisol in plastic container, multiple electrolytes injection type 1 usp ph 5.5, plasma-lyte 148 in water in plastic container, prismasol bgk 2/0 in plastic container, trilyte, nulytely-flavored, normocarb hf 35, aminosyn 3.5% m, aminosyn ii 10% w/ electrolytes, lax-lyte with flavor packs, prismasol bk 0/0/1.2 in plastic container, tpn electrolytes in plastic container, prismasol bk 0/0 in plastic container, prismasol b22gk 2/2.5 in plastic container, tham-e, travasol 3.5% w/ electrolytes, travasol 8.5% sulfite free w/ electrolytes in plastic container, clenz-lyte, peg-lyte, colovage, prismasol b22gk 4/0 in plastic container, aminosyn ii 3.5% m, freamine iii 3% w/ electrolytes, co-lav, acetated ringer's in plastic container, aminosyn 8.5% w/ electrolytes, aminosyn ii 8.5% w/electrolytes, travasol 8.5% w/ electrolytes, multiple electrolytes injection type 1 usp ph 7.4, bss plus, physiosol in plastic container, prismasol bgk 2/3.5 in plastic container, phoxillum bk 4/2.5 in plastic container, elliotts b solution, cardioplegic in plastic container, prismasol bk 4/2.5 in plastic container, travasol 5.5% w/ electrolytes, synovalyte in plastic container, ocl, plasma-lyte a in plastic container, prismasol bgk 4/0/1.2 in plastic container, navstel, prismasol bgk 0/2.5 in plastic container, normocarb hf 25, suclear
Latest Update: 2024-09-10
Latest Update Note: Clinical Trial Update

Product Description

Sodium chloride is an inorganic chloride salt having sodium(1+) as the counterion. It has a role as an emetic and a flame retardant. It is an inorganic chloride and an inorganic sodium salt. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-chloride)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Norgine
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sodium chloride

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Kenya, Korea, Latvia, Lithuania, Malawi, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Uganda, Ukraine, United Kingdom, United States, Unknown Location, Zimbabwe

Active Clinical Trial Count: 136

Highest Development Phases

Phase 3: Abdominal Pain|Abscess|Acute Myeloid Leukemia|Acute Pain|Adenocarcinoma|Allogeneic Stem Cell Transplant|Asthma, Allergic|Ataxia Telangiectasia|Bladder Cancer|Breast Cancer|Bronchiectasis|Bronchitis, Chronic|COVID-19|Cancer Pain|Cerebellar Ataxia|Cervical Intraepithelial Neoplasia|Chronic Obstructive Pulmonary Disease|Chronic Pain|Colorectal Cancer|Communicable Diseases|Conjunctivitis, Allergic|Crohn Disease|Dust mite Hypersensitivity|Emphysema|Endometritis|Environmental Hypersensitivity|Esophageal Cancer|Gastrointestinal Cancer|HIV Infections|Healthy Volunteers|Heart Failure|Hematopoietic Stem Cell Transplant|Inflammation|Influenza, Human|Injuries/wounds Unspecified|Ischemic Stroke|Keratoconjunctivitis Sicca|Kidney Diseases|Kidney Failure, Chronic|Kidney Transplant|Liver Cancer|Low Back Pain|Meningitis|Myasthenia Gravis|Myelofibrosis|Neuralgia|Non-Small-Cell Lung Cancer|Obesity|Oophoritis|Other|Ovarian Diseases|Overweight|Pain Unspecified|Pain, Postoperative|Papillomavirus Infections|Peritonitis|Pleural Effusion, Malignant|Pneumonia|Polycythemia|Respiratory Syncytial Virus Infections|Respiratory Tract Infections|Rhinitis, Allergic|Salpingitis|Sleep Apnea, Obstructive|Small Cell Lung Cancer|Squamous Intraepithelial Lesions of the Cervix|Thrombocythemia, Essential|Thrombocytopenia|Total Knee Arthroplasty|Traumatic Brain Injury|Urinary Calculi|Urinary Tract Infections|Venous Thromboembolism|alpha 1-Antitrypsin Deficiency

Phase 2: Acute Coronary Syndrome|Alzheimer Disease|Brain Injuries|Bronchopulmonary Dysplasia|Cardiac Arrest|Chickenpox|Fatty Liver, Alcoholic|Glabellar Reflex|Gonorrhea|Hepatitis B, Chronic|Hepatitis E|Herpes Zoster|Hypotension, Orthostatic|Intestinal Diseases|Lupus Nephritis|Lymphoma|Morphine Dependence|Non-alcoholic Fatty Liver Disease|Orthostatic Intolerance|Paresthesia|Pseudomonas Infections|Pyelonephritis|Scleroderma, General|Severe Acute Respiratory Syndrome|Sexually Transmitted Diseases|Spondylitis, Ankylosing|Staphylococcal Infections|Surgical Wound Infection|beta-Thalassemia

Phase 1: Acute Lung Injury|Adenoviridae Infections|Amyotrophic Lateral Sclerosis|Anesthesia Related|Angina Pectoris|Appendicitis|Arthritis, Rheumatoid|Atrial Fibrillation|Bacteroides Infections|Cerebral Hemorrhage|Clostridium Infections|Coronary Disease|Depressive Disorder, Major|Edema|Fusobacterium Infections|Hyperparathyroidism, Secondary|Lyme Disease|Myocardial Infarction|Osteoarthritis, Knee|Pelvic Infection|Pelvic Inflammatory Disease|Psoriasis|Stroke|Tetanus|Type 1 Diabetes|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EVENEW

P2

Recruiting

Bronchopulmonary Dysplasia

2028-06-30

VAC52416BAC3001

P3

Not yet recruiting

Urinary Tract Infections

2028-06-30

CN008-0003

P2

Not yet recruiting

Alzheimer Disease

2027-11-16

2022/0270/HP

P3

Not yet recruiting

Pain, Postoperative

2027-10-01

Recent News Events